MarketPeel
Insider Trading Intelligence
Pricing
…
EB

Epperly Melissa B.

NAUT
DIRECTOR · NAUTILUS BIOTECHNOLOGY, INC. · CIK 0001807359
FILING MIX · LIFETIME40%/60%
BUYS
37
SELLS
56
TOTAL VALUE
$7.99M
COMPANIES
3
ACTIVE SINCE
Apr 2020
HOLDINGS NOW
515,671
AVG SELL PX
$38.74
TRADE KIND
SHOWING 93 / 93
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
50 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Epperly Melissa B., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d50+70.00%-3.35%+0.32%-3.67%-2.44%-1.93
14d50+62.00%-4.07%+0.54%-4.61%-5.12%-1.83
30d50+56.00%-1.34%+1.35%-2.69%-1.19%-0.90
60d50+72.00%-7.44%+3.35%-10.79%-21.24%-2.78
90d50+66.00%-3.17%+3.73%-6.89%-20.72%-1.73
180d50(1 pending)+42.86%+8.64%+9.39%-0.74%-9.15%-0.15
1y50(1 pending)+48.98%-9.24%+14.02%-23.25%-33.50%-3.69
2y50(1 pending)+95.92%-58.70%+15.83%-74.54%-70.29%-17.25
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NAUT · 45,000 shares · as of Jun 18, 2026
021,61743,23464,85086,4672023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 37 buys / 56 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ROIV
ROIVANT SCIENCES LTD.
SALE10b5-1
10b5-1 plan
15,002$34.32$514.9K19,222Jun 29, 2026Jul 1, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASE
17,750$4.46$79.2K34,224Jun 29, 2026Jul 1, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE10b5-1
10b5-1 plan
2,748$34.71$95.4K16,474Jun 29, 2026Jul 1, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
17,750——169,166Jun 29, 2026Jul 1, 2026 ↗View →
NAUT
NAUTILUS BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jun 18, 2026Jun 22, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
670——16,474Apr 17, 2026Apr 21, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
41,861$28.68$1.20M15,804Mar 16, 2026Mar 18, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
54$22.98$1.2K57,665Jan 20, 2026Jan 22, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
815——57,719Jan 20, 2026Jan 22, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,056——56,904Oct 20, 2025Oct 22, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
33,726——33,726Sep 10, 2025Sep 12, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
1,661$13.77$22.9K55,848Sep 10, 2025Sep 12, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
14,524——57,509Sep 10, 2025Sep 12, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,609——42,985Jul 17, 2025Jul 21, 2025 ↗View →
NAUT
NAUTILUS BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jun 23, 2025Jun 24, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,847——41,376Apr 17, 2025Apr 21, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
180$11.21$2.0K39,529Jan 23, 2025Jan 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,672——39,709Jan 23, 2025Jan 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,613——38,037Oct 21, 2024Oct 23, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
4,245$12.12$51.4K36,424Sep 12, 2024Sep 16, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
16,406——40,669Sep 10, 2024Sep 12, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
27,894——27,894Sep 10, 2024Sep 12, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,702——24,263Jul 23, 2024Jul 25, 2024 ↗View →
NAUT
NAUTILUS BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jun 14, 2024Jun 17, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
123$10.90$1.3K22,561Apr 24, 2024Apr 26, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,146——22,684Apr 24, 2024Apr 26, 2024 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,573$11.44$29.4K451,449Feb 12, 2024Feb 12, 2024 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
8,669$11.54$100.0K454,022Feb 2, 2024Feb 5, 2024 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
75,000——462,691Feb 1, 2024Feb 5, 2024 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
75,000——75,000Feb 1, 2024Feb 5, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,207——21,538Jan 19, 2024Jan 23, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
1,226——20,331Oct 16, 2023Oct 18, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,594$19.43$89.2K388,579Oct 4, 2023Oct 6, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
888$19.91$17.7K387,691Oct 4, 2023Oct 6, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
17,825——19,105Sep 12, 2023Sep 14, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
26,595——26,595Sep 12, 2023Sep 14, 2023 ↗View →
NAUT
NAUTILUS BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jun 15, 2023Jun 16, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
5,227$19.98$104.4K392,048Feb 14, 2023Feb 14, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,624$20.42$53.6K397,275Feb 13, 2023Feb 14, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
148,043——148,043Feb 1, 2023Feb 1, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
101,957——399,899Feb 1, 2023Feb 1, 2023 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
50,000——297,543Oct 3, 2022Oct 3, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
186,916——186,916Jul 20, 2022Jul 25, 2022 ↗View →
NAUT
NAUTILUS BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
86,467——86,467Jun 15, 2022Jun 16, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,818$50.70$142.9K252,279Apr 4, 2022Apr 5, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
4,512$51.99$234.6K247,767Apr 4, 2022Apr 5, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
8,094$48.75$394.6K256,400Apr 4, 2022Apr 5, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
353$52.44$18.5K247,414Apr 4, 2022Apr 5, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,303$49.90$65.0K255,097Apr 4, 2022Apr 5, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,211$48.81$59.1K265,196Feb 23, 2022Feb 23, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
702$49.59$34.8K264,494Feb 23, 2022Feb 23, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,405——266,407Feb 10, 2022Feb 14, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
38,489——38,489Feb 10, 2022Feb 14, 2022 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
17,080$67.13$1.15M250,002Oct 2, 2021Oct 4, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
8,285$52.00$430.8K266,685Aug 19, 2021Aug 18, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
1,326$52.00$68.9K258,400Aug 18, 2021Aug 18, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
700$50.10$35.1K259,457Jul 1, 2021Jul 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
805$52.01$41.9K257,274Jul 1, 2021Jul 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,378$51.15$70.5K258,079Jul 1, 2021Jul 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
200$53.19$10.6K257,074Jul 1, 2021Jul 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
200$54.90$11.0K260,157Jun 1, 2021Jun 2, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,883$53.99$155.7K260,357Jun 1, 2021Jun 2, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
661$58.04$38.4K265,312May 3, 2021May 5, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
950$59.83$56.8K264,362May 3, 2021May 5, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,122$60.14$67.5K263,240May 3, 2021May 5, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
350$56.99$19.9K265,973May 3, 2021May 5, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,083$43.43$133.9K280,347Apr 5, 2021Apr 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
13,792$43.37$598.1K266,555Apr 5, 2021Apr 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
83$45.06$3.7K266,323Apr 5, 2021Apr 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
149$44.21$6.6K266,406Apr 5, 2021Apr 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,083$41.67$128.5K283,430Mar 1, 2021Mar 3, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,000——286,513Feb 11, 2021Feb 16, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Feb 11, 2021Feb 16, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,700$37.45$101.1K271,896Feb 1, 2021Feb 3, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
383$38.33$14.7K271,513Feb 1, 2021Feb 3, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
800$50.36$40.3K276,879Jan 4, 2021Jan 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
600$51.58$30.9K276,279Jan 4, 2021Jan 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
100$53.20$5.3K274,596Jan 4, 2021Jan 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,583$52.73$83.5K274,696Jan 4, 2021Jan 6, 2021 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
971$52.53$51.0K283,053Dec 7, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
4,983$53.71$267.6K278,070Dec 7, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
119$50.84$6.0K284,024Dec 7, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
391$54.39$21.3K277,679Dec 7, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,343$50.76$169.7K288,020Dec 4, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,877$51.17$198.4K284,143Dec 4, 2020Dec 8, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
500$52.27$26.1K291,721Dec 2, 2020Dec 3, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
700$50.34$35.2K293,746Dec 2, 2020Dec 3, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
358$53.17$19.0K291,363Dec 2, 2020Dec 3, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,525$51.33$78.3K292,221Dec 2, 2020Dec 3, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
300$47.26$14.2K294,446Nov 23, 2020Nov 25, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,783$46.51$129.4K294,746Nov 23, 2020Nov 25, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
147,394——277,529Apr 7, 2020Apr 9, 2020 ↗View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
20,000$18.00$360.0K297,529Apr 7, 2020Nov 25, 2020 ↗View →
Other insiders · NAUT
Loading peer insiders…
About this filer
CIK 0001807359
ROLE
Director
PRIMARY
NAUT
COMPANIES
3
ACTIVE SINCE
Apr 2020
MARKETPEEL · /INSIDER/0001807359DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback